Cargando…
Reducing the number of CTs performed to monitor personalized dosimetry during peptide receptor radionuclide therapy (PRRT)
BACKGROUND: Peptide receptor radionuclide therapy (PRRT) with [(177)Lu]-DOTA-TATE is an effective treatment of neuroendocrine tumors (NETs). After each cycle of treatment, patient dosimetry evaluates the radiation dose to the risk organs, kidneys, and bone marrow, the most radiosensitive tissues. Ab...
Autores principales: | Chicheportiche, Alexandre, Artoul, Faozi, Schwartz, Arnon, Grozinsky-Glasberg, Simona, Meirovitz, Amichay, Gross, David J., Godefroy, Jeremy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6006002/ https://www.ncbi.nlm.nih.gov/pubmed/29916115 http://dx.doi.org/10.1186/s40658-018-0211-1 |
Ejemplares similares
-
Dosimetry after peptide receptor radionuclide therapy: impact of reduced number of post-treatment studies on absorbed dose calculation and on patient management
por: Chicheportiche, Alexandre, et al.
Publicado: (2020) -
Simple model for estimation of absorbed dose by organs and tumors after PRRT from a single SPECT/CT study
por: Chicheportiche, Alexandre, et al.
Publicado: (2021) -
Predictive power of the post-treatment scans after the initial or first two courses of [(177)Lu]-DOTA-TATE
por: Chicheportiche, Alexandre, et al.
Publicado: (2018) -
Can a penalized-likelihood estimation algorithm be used to reduce the injected dose or the acquisition time in (68)Ga-DOTATATE PET/CT studies?
por: Chicheportiche, Alexandre, et al.
Publicado: (2021) -
Prognostic Factors in Advanced Adrenocortical Carcinoma: Summary of a National Referral Center’s 20 years of Experience
por: Arnon, Johnathan, et al.
Publicado: (2022)